BRAF inhibitors in cancer therapy

Pharmacology and Therapeutics

Volumn 142, Issue 2, 2014, Pages 176-182

  Hertzman Johansson, Carolina ^a   Egyhazi Brage, Suzanne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BRAF inhibitors; BRAF mutation; Cancer therapy; Combination therapy; Resistance mechanisms

Indexed keywords

ARQ 736; ARRY 438162; B RAF KINASE INHIBITOR; CEP 32496; CETUXIMAB; CHIR 265; DABRAFENIB; IPILIMUMAB; LGX 818; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RO 5126766; RO 5212054; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; XL 281;

ALTERNATIVE RNA SPLICING; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; COLON CANCER; GENE MUTATION; MELANOMA; METASTATIC MELANOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW;

BRAF INHIBITORS; BRAF MUTATION; CANCER THERAPY; COMBINATION THERAPY; RESISTANCE MECHANISMS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84896391403     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2013.11.011     Document Type: Review

References (91)

1. P.A. Ascierto, E. Simeone, D. Giannarelli, A.M. Grimaldi, A. Romano, and N. Mozzillo Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use J Transl Med 10 2012 107
2. A.D. Ballantyne, and K.P. Garnock-Jones Dabrafenib: first global approval Drugs 73 2013 1367 1376
3. S. Bhaskaran, K.V. Dileep, S.S. Deepa, C. Sadasivan, M. Klausner, and N.K. Krishnegowda et al. Gossypin as a novel selective dual inhibitor of V-RAF murine sarcoma viral oncogene homolog B1 and cyclin-dependent kinase 4 for melanoma Mol Cancer Ther 12 2013 361 372
4. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, and H. Cho et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
5. A. Boni, A.P. Cogdill, P. Dang, D. Udayakumar, C.N. Njauw, and C.M. Sloss et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function Cancer Res 70 2010 5213 5219
6. M.S. Brose, P. Volpe, M. Feldman, M. Kumar, I. Rishi, and R. Gerrero et al. BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
7. M.K. Callahan, R. Rampal, J.J. Harding, V.M. Klimek, Y.R. Chung, and T. Merghoub et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment N Engl J Med 367 2012 2316 2321
8. D. Chakravarty, E. Santos, M. Ryder, J.A. Knauf, X.H. Liao, and B.L. West et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation J Clin Invest 121 2011 4700 4711
9. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, and J. Larkin et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
10. E.F. Choo, J.P. Driscoll, J. Feng, B. Liederer, E. Plise, and N. Randolph et al. Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species Xenobiotica 39 2009 700 709
11. R.B. Corcoran, H. Ebi, A.B. Turke, E.M. Coffee, M. Nishino, and A.P. Cogdill et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov 2 2012 227 235
12. R.B. Corcoran, G.S. Falchook, J.R. Infante, O. Hamid, W.A. Messersmith, and E.L. Kwak et al. BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212) J Clin Oncol 30 2012 3528 (Suppl.; abstr)
13. R.B. Corcoran, S.M. Rothenberg, A.N. Hata, A.C. Faber, A. Piris, and R.M. Nazarian et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma Sci Transl Med 5 2013 196 198
14. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
15. T. Eisen, T. Ahmad, K.T. Flaherty, M. Gore, S. Kaye, and R. Marais et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Br J Cancer 95 2006 581 586
16. C.M. Emery, K.G. Vijayendran, M.C. Zipser, A.M. Sawyer, L. Niu, and J.J. Kim et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc Natl Acad Sci U S A 106 2009 20411 20416
17. G.S. Falchook, G.V. Long, R. Kurzrock, K.B. Kim, T.H. Arkenau, and M.P. Brown et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 2012 1893 1901
18. G.S. Falchook, J.C. Trent, M.C. Heinrich, C. Beadling, J. Patterson, and C.C. Bastida et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance Oncotarget 4 2013 310 315
19. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, and J. Sosman et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
20. K.T. Flaherty, I. Puzanov, K.B. Kim, A. Ribas, G.A. McArthur, and J.A. Sosman et al. Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
21. K. Fransen, M. Klintenas, A. Osterstrom, J. Dimberg, H.J. Monstein, and P. Soderkvist Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas Carcinogenesis 25 2004 527 533
22. D.T. Frederick, A. Piris, A.P. Cogdill, Z.A. Cooper, C. Lezcano, and C.R. Ferrone et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma Clin Cancer Res 19 2013 1225 1231
23. M.R. Girotti, M. Pedersen, B. Sanchez-Laorden, A. Viros, S. Turajlic, and D. Niculescu-Duvaz et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma Cancer Discov 3 2013 158 167
24. W.O. Greaves, S. Verma, K.P. Patel, M.A. Davies, B.A. Barkoh, and J.M. Galbincea et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma J Mol Diagn 15 2013 220 226
25. J.G. Greger, S.D. Eastman, V. Zhang, M.R. Bleam, A.M. Hughes, and K.N. Smitheman et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol Cancer Ther 11 2012 909 920
26. A. Guerra, M.R. Sapio, V. Marotta, E. Campanile, S. Rossi, and I. Forno et al. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma J Clin Endocrinol Metab 97 2012 517 524
27. R. Halaban, W. Zhang, A. Bacchiocchi, E. Cheng, F. Parisi, and S. Ariyan et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells Pigment Cell Melanoma Res 23 2010 190 200
28. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
29. A. Hauschild, S.S. Agarwala, U. Trefzer, D. Hogg, C. Robert, and P. Hersey et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2009 2823 2830
30. A. Hauschild, J.J. Grob, L.V. Demidov, T. Jouary, R. Gutzmer, and M. Millward et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
31. S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, and N. Dhomen et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
32. K.P. Hoeflich, S. Herter, J. Tien, L. Wong, L. Berry, and J. Chan et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression Cancer Res 69 2009 3042 3051
33. J. James, B. Ruggeri, R.C. Armstrong, M.W. Rowbottom, S. Jones-Bolin, and R.N. Gunawardane et al. CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity Mol Cancer Ther 11 2012 930 941
34. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, and L.A. Johnson et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
35. M.F. Kalady, K.L. Dejulius, J.A. Sanchez, A. Jarrar, X. Liu, and E. Manilich et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis Dis Colon Rectum 55 2012 128 133
36. F.M. Kaplan, Y. Shao, M.M. Mayberry, and A.E. Aplin Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells Oncogene 30 2011 366 371
37. K.B. Kim, M.E. Cabanillas, A.J. Lazar, M.D. Williams, D.L. Sanders, and J.L. Ilagan et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF mutation Thyroid 23 10 2013 1277 1283
38. M. Kobayashi, M. Sonobe, T. Takahashi, A. Yoshizawa, M. Ishikawa, and R. Kikuchi et al. Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer Anticancer Res 31 2011 4619 4623
39. S. Kopetz, J. Desai, E. Chan, J.R. Hecht, P.J. O'Dwyer, and R.J. Lee et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors J Clin Oncol 28 No 15-suppl 2010 3534
40. R.C. Koya, S. Mok, N. Otte, K.J. Blacketor, B. Comin-Anduix, and P.C. Tumeh et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy Cancer Res 72 2012 3928 3937
41. M. Kudo, and K. Ueshima Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan Oncology 78 Suppl. 1 2010 154 166
42. S.E. Langabeer, D. O'Brien, A.M. McElligott, M. Lavin, and P.V. Browne BRAF V600E-negative hairy cell leukaemia Case Rep Hematol 2013 2013 513049
43. J.A. Laurini, P. Aoun, J. Iqbal, W. Chan, and T.C. Greiner Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders Am J Clin Pathol 138 2012 877 883
44. K. Le, E.S. Blomain, U. Rodeck, and A.E. Aplin Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells Pigment Cell Melanoma Res 26 2013 509 517
45. C. Li, K.C. Lee, E.B. Schneider, and M.A. Zeiger BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis J Clin Endocrinol Metab 97 2012 4559 4570
46. C. Liu, W. Peng, C. Xu, Y. Lou, M. Zhang, and J.A. Wargo et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice Clin Cancer Res 19 2013 393 403
47. M. Martinez-Garcia, U. Banerji, J. Albanell, R. Bahleda, S. Dolly, and F. Kraeber-Bodere et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors Clin Cancer Res 18 2012 4806 4819
48. C. Montagut, S.V. Sharma, T. Shioda, U. McDermott, M. Ulman, and L.E. Ulkus et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res 68 2008 4853 4861
49. C. Montero-Conde, S. Ruiz-Llorente, J.M. Dominguez, J.A. Knauf, A. Viale, and E.J. Sherman et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas Cancer Discov 3 2013 520 533
50. J. Munoz, E. Schlette, and R. Kurzrock Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation J Clin Oncol 31 2013 e351 e352
51. K.L. Nathanson, A.M. Martin, B. Wubbenhorst, J. Greshock, R. Letrero, and K. D'Andrea et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436) Clin Cancer Res 19 2013 4868 4878
52. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
53. S. Ogino, K. Shima, J.A. Meyerhardt, N.J. McCleary, K. Ng, and D. Hollis et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803 Clin Cancer Res 18 2012 890 900
54. M. Okaniwa, M. Hirose, T. Arita, M. Yabuki, A. Nakamura, and T. Takagi et al. Discovery of a selective kinase inhibitor (TAK-632) targeting Pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives J Med Chem 56 2013 6478 6494
55. M. Okaniwa, M. Hirose, T. Imada, T. Ohashi, Y. Hayashi, and T. Miyazaki et al. Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds J Med Chem 55 2012 3452 3478
56. K. Omholt, E. Grafstrom, L. Kanter-Lewensohn, J. Hansson, and B.K. Ragnarsson-Olding KIT pathway alterations in mucosal melanomas of the vulva and other sites Clin Cancer Res 17 2011 3933 3942
57. K.H. Paraiso, H.E. Haarberg, E. Wood, V.W. Rebecca, Y.A. Chen, and Y. Xiang et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Clin Cancer Res 18 2012 2502 2514
58. K.H. Paraiso, Y. Xiang, V.W. Rebecca, E.V. Abel, Y.A. Chen, and A.C. Munko et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression Cancer Res 71 2011 2750 2760
59. C. Peyssonnaux, and A. Eychene The Raf/MEK/ERK pathway: new concepts of activation Biol Cell 93 2001 53 62
60. A. Platz, S. Egyhazi, U. Ringborg, and J. Hansson Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site Mol Oncol 1 2008 395 405
61. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
62. A. Prahallad, C. Sun, S. Huang, F. Di Nicolantonio, R. Salazar, and D. Zecchin et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
63. A. Ribas, F.S. Hodi, M. Callahan, C. Konto, and J. Wolchok Hepatotoxicity with combination of vemurafenib and ipilimumab N Engl J Med 368 2013 1365 1366
64. E. Romano, S. Pradervand, A. Paillusson, J. Weber, K. Harshman, and K. Muehlethaler et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression Clin Cancer Res 19 20 2013 5749 5757
65. M.W. Rowbottom, R. Faraoni, Q. Chao, B.T. Campbell, A.G. Lai, and E. Setti et al. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3- (5-(1,1,1-trifluoro-2-methylpropa n-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E J Med Chem 55 2012 1082 1105
66. C.M. Rudin, K. Hong, and M. Streit Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer J Thorac Oncol 8 2013 e41 e42
67. S. Rush, N. Foreman, and A. Liu Brainstem ganglioglioma successfully treated with vemurafenib J Clin Oncol 31 2013 e159 e160
68. W.S. Samowitz, C. Sweeney, J. Herrick, H. Albertsen, T.R. Levin, and M.A. Murtaugh et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 65 2005 6063 6069
69. G. Schindler, D. Capper, J. Meyer, W. Janzarik, H. Omran, and C. Herold-Mende et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma Acta Neuropathol 121 2011 397 405
70. G.K. Schwartz, S. Robertson, A. Shen, E. Wang, L. Pace, and H. Dials et al. A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors J Clin Oncol 27 2009 15s
71. H. Shi, G. Moriceau, X. Kong, M.K. Lee, H. Lee, and R.C. Koya et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat Commun 3 2012 724
72. N.L. Sieben, P. Macropoulos, G.M. Roemen, S.M. Kolkman-Uljee, G. Jan Fleuren, and R. Houmadi et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours J Pathol 202 2004 336 340
73. G. Singer, R. Oldt III, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
74. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, and J.S. Weber et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
75. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z.R. Qian, and J. Du et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
76. D.D. Stuart, N. Li, D.J. Poon, K. Aardalen, S. Kaufman, and H. Hanne Merritt et al. Preclinical profile of LGX818: a potent and selective RAF kinase inhibitor Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research 72 2012 (Suppl.)
77. Y. Su, A.E. Vilgelm, M.C. Kelley, O.E. Hawkins, Y. Liu, and K.L. Boyd et al. RAF265 inhibits the growth of advanced human melanoma tumors Clin Cancer Res 18 2012 2184 2198
78. F. Su, A. Viros, C. Milagre, K. Trunzer, G. Bollag, and O. Spleiss et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N Engl J Med 366 2012 207 215
79. R.J. Sullivan, and K.T. Flaherty Resistance to BRAF-targeted therapy in melanoma Eur J Cancer 49 2013 1297 1304
80. E. Tiacci, V. Trifonov, G. Schiavoni, A. Holmes, W. Kern, and M.P. Martelli et al. BRAF mutations in hairy-cell leukemia N Engl J Med 364 2011 2305 2315
81. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
82. S. Whittaker, D. Menard, R. Kirk, L. Ogilvie, D. Hedley, and A. Zambon et al. A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF Cancer Res 70 2010 8036 8044
83. S.R. Whittaker, J.P. Theurillat, E. Van Allen, N. Wagle, J. Hsiao, and G.S. Cowley et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition Cancer Discov 3 2013 350 362
84. J.S. Wilmott, G.V. Long, J.R. Howle, L.E. Haydu, R.N. Sharma, and J.F. Thompson et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma Clin Cancer Res 18 2012 1386 1394
85. J.S. Wilmott, R.A. Scolyer, G.V. Long, and P. Hersey Combined targeted therapy and immunotherapy in the treatment of advanced melanoma Oncoimmunology 1 2012 997 999
86. M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R.L. Shapiro, and R.S. Berman et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma PLoS One 7 2012 e29336
87. H. Yang, B. Higgins, K. Kolinsky, K. Packman, W.D. Bradley, and R.J. Lee et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer Cancer Res 72 2012 779 789
88. T. Yokota, T. Ura, N. Shibata, D. Takahari, K. Shitara, and M. Nomura et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer Br J Cancer 104 2011 856 862
89. K. Young, A. Minchom, and J. Larkin BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation Future Oncol 8 2012 499 507
90. Y. Yu, X. Zhao, X. Gu, E. Chang, L. Cousens, and E. Chiesa et al. Pharmacodynamic biomarkers for ARQ 736, a small molecule BRAF inhibitor Proceedings of the 101rd Annual Meeting of the American Association for Cancer Research 70 2010 (Suppl.)
91. A. Zebary, K. Omholt, I. Vassilaki, V. Hoiom, D. Linden, and L. Viberg et al. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma J Dermatol Sci 72 3 2013 284 289